GUT Microbiota in health and disease Moderator – Dr Sunil K Mathai Panelists – Dr Benoy Sebastian, Dr Geetha M, Dr Antony Chettupuzha, Dr Joseph John GUT : How sterile is it? – AC Sterile at birth… Gut Microbiota Number of intestinal microbial cells is 10 times greater than the number of human body cells Approximately 150 times larger than the human gene complement, with an estimated set of 3.3 million microbial gene Bacteroides Firmicutes Fusobacteria Verrucomicrobia Proteobacteria Cyanobacteria Actinobacteria Infant feeding: Role in development of GUT microbiota - GM Infant feeding – Role in devpt of microbiota • Best microbiota in babies born by vaginal delivery , roomed-in with mother & breast-fed • Worst in ceasarian delivery, admitted in ICU, formula-fed and administered IV antibiotics GUT Microbiota a Vital organ – BS Microbial ecosystem • Upto 100 trillion bacteria - 500 different species • Outnumber human somatic and germ cells by 10 fold • Marked microbial diversity among different individuals • Each person has his own distinctive pattern of microbial composition • Determined by genetic and environmental factors Hidden Metabolic Organ Protective Function • • • • Pathogen Displacement Antimicrobial factors Immune system development Promotes anti inflammatory cytokines and down regulates pro inflammatory cytokines • Induces regulatory T cells Structural Functions • • • • Barrier Fortification Induction of IgA Apical tightening of tight junction Enhanced mucin prodution Metabolic Functions • • • • Short chain fatty acids Metabolizes dietary carcinogens Synthesis of vitamins Ion absorption GUT Microbiota in Growth and Development – GM GUT microbiota in growth and development • Gut and microbiotia – symbiotic relationship • Modulates gut immune system via “ crosstalk” • In the newborn period commensal bacteria provide the immune system with stimuli which causes maturation • If you get the right bacteria – prevents a number of AI conditions, atopy, allergy etc GUT dysbiosys – Good, Bad and Ugly – JJ Good • Dysbiosis is a state in which the microbiota becomes altered due to an alteration in the composition of the microbiota, a change in bacterial metabolic activity and/or a shift in local distribution of communities. • Role in several diseases. • Factors altering the gastrointestinal ecosystem include • antibiotics, • psychological and physical stresses, • radiation, • altered peristalsis and • dietary changes Bad Ugly Probiotic, Prebiotic and Synbiotic – The concept – AC Probiotic means for life… WHO definition(2001): “Live micro-organisms which, when administered in adequate amounts, confer a health benefit on the host” Sour milk with lactobacilli prolongs life 1907 Ilya Ilyich Mechnikov Lilly, D. M. and R. H. Stillwell. 1965. Probiotics: growth promoting factors produced by microorganisms. Science 147:747-748 Parker, R. B. 1974. Probiotics, the other half of the antibiotic story. Anim. Nutr. Health. 29:4-8 Fuller, R. 1989. Probiotics in man and animals. J. Appl. Bacteriol. 66:365-378 Prebiotic Definition: “A dietary prebiotic is a selectively fermented ingredient that results in specific changes, in the composition and/or activity of the gastrointestinal microbiota, thus conferring benefit(s) upon host health.” They are dietary fibers with a wellestablished positive impact on the intestinal microflora Term coined by Glen Gibson 1995 Non-digestible Oligosaccharides Inulin Oligofructose (trans)galactooligosaccharides Synbiotics Selection of a Probiotic candidate – Which organism and why – BS • A probiotic strain is identified by the genus, species, and an alphanumeric designation An ideal probiotic • Able to survive the passage through the digestive system • Able to attach to the intestinal epithelia and colonise. • Able to maintain good viability • Able to utilise the nutrients and substrates in a normal diet • Non pathogenic and non toxic • Capable of exerting a benificial effect on the host • Stability of desired characteristics during processing, storage and transportation Clinically Useful strains • Lactobacillus sp. – reuteri – casei – ramnosus – Acidophilus • Streptococcus sp. • Bifidobacterium sp. – Infantis (breastmilk) – lactis – longum – breve – bifidum • Sacharomyces boulardii • Enterococcus sp • Mixtures Before marketing • Purified strain of microbe • In vivo safety and efficacy studies in animals • In vivo safety,efficacy and effectiveness studies in human beings Labeling Requirements • Genus,species and strains • Minimum valuable number of each probiotic strain at which efficacy is claimed • Shelf life • Evidence based health claims • Serving size • Storage conditions Mechanism of action of Probiotics JJ • • • • • • • • • • Antimicrobial actions: Inhibit growth of pathogenic enteric bacteria by: Decreasing luminal pH Secreting bactericidal proteins Resisting colonisation Competing for nutrients with pathogens Modifying pathogen-derived toxins Stimulating defensin production Blocking epithelial binding Stimulating mucus production • • • • • • • • • • • • Barrier function: Improve epithelial and mucosal barrier function by: Producing SCFAs Increase barrier integrity Enhance mucus production Immune function: Alter host immune response by: Modulating cytokine profiles - induce IL-10 and TGF- secretion and decrease TNF and IFN- expression Activating local macrophages and increase secretory IgA production both locally and systemically Activating Treg cells Inducing hyporesponsiveness to food antigens Dampening inflammatory responses Daily Kerala diet; Is it probiotic rich? GM Daily Kerala Diet – is it probiotic rich? • Traditional fare – – Fermented rice – Healthy and “prebiotic rich” • Newer diets – Neither healthy nor probiotic rich – Added probiotics may benefit Available probiotic preparations; are all the same? AC Probiotic Platter Are all the same? Indications of Probiotics in Adults BS Irritable Bowel syndrome • Metaanalysis - Moyyedi et al Gut 2010 • 19 RCTs – 1650 patients • Significant reduction in symptoms with an NNT of 4 • Trend towards improving pain and bloating • No effect on constipation • Bifidobacterium infantis 35624 – superior Diarrhoea Clinical condition Effectiveness Organisms Infectious Diarrhoea A S.boulardii,LGG Prevention of Antibiotic associated diarrhoea Prevention of PMC A S.boulardii,LGG,L.ca sei,S.thermophilus B LGG,S.boulardii Treatment of PMC B LGG,S.boulardii Prophylaxis of Travellers Dirrhoea B LGG,S.boulardii Inflammatory Bowel Disease • Yet to meet the high expectations predicted by the theoretical data • No significant or consistent benefit in Crohn’s disease • In UC a modest effect in inducing and maintaining remession in mild to moderate UC • Escherichia coli Nissle and VSL # 3 Pouchitis • Significant reduction first episode of pouchitis • Maintenance of remission of recurrent or refractory pouchitis • Used VSL # 3 Gosselink etal Dis Colon Rectum 2004 Mimura et al Gut 2004 Other GI Diseases Disease Comments H.Pylori Significant reduction in AAD.No difference in eradication rates Lactose Intolerance Significant benefit Hepatic Encephalopathy NASH Role in MHE.Lactulose – a prebiotic No proven in overt HE Emerging data Radiation Enteritis Effect is only minimal Indications of Probiotics in infants and Children GM Indications of probiotics in Infants an children • Definite indications – Antibiotic induced diarrhoea (Probiotics for the Prevention and Treatment of Antibiotic-Associated Diarrhea - A Systematic Review and Meta-analysis. JAMA. 2012) – Traveller’s diarrhoea – Rotaviral Diarrhoea – Necrotizing Enterocolitis (Probiotics Reduce All-Cause Mortality and Necrotizing Enterocolitis. Pediatrics 2010) • Other indications ( Value not proven) – IBD – IBS – H Pylori Dosage and Administration of Probiotics; Issues to consider JJ • Pay close attention to the strain (not just the genus and species). • Different probiotic strains exert their beneficial effects via different mechanisms and may be synergistic with other microbiota. • Studies have used doses ranging from 2 × 107 colonyforming units (CFU) per day to 3.2 × 1012 CFU per day. • No uniform dosing recommendations. • Frequency can range from twice daily to intermittent weekly. • Probiotic strains are generally safe. • Lactobacilli and bifidobacteria are normal commensals of the GI tract. • Because probiotics are viable microorganisms, they have the potential to cause invasive infections in hosts with compromised mucosal epithelia. • Should be used with caution in children, elderly persons and individuals with major risk factors. Disorder, action Probiotic strain / prebiotic Recommended dose Maintenance of remission in ulcerative colitis Escherichia coli Nissle 1917 5 × 1010 viable bac, twice daily Treatment of mildly active ulcerative colitis or pouchitis VSL# 3 mixture of eight strains (one S. 2 × 9 × 1011 thermophilus, four Lactobacillus, cfu, twice daily three Bifidobacterium) Prevention and maintenance of remission in pouchitis VSL# 3 mixture of eight strains (one S. 2 × 4.5 ×1011 thermophilus, four Lactobacillus, cfu, twice daily three Bifidobacterium) Alleviates some symptoms of irritable bowel syndrome Bifidobacterium infantis 35624 108 cfu, once daily B. longum 101 (29%), L. acidophilus 102 (29%), Lactococcus lactis 103 (29%), and S. thermophilus 104(13%) 1010 cfu, once daily Enterococcus faecium LAB SF68 108 cfu, three times daily Saccharomyces. boulardii, strain of S. cerevisiae 109 cfu per capsule of 250mg, 2–6 capsules per day Treatment of acute diarrhea in adults Disorder, action Probiotic strain / prebiotic Recommended dose Prevention of antibiotic associated diarrhea in adults E. faecium LAB SF68 108 cfu, twice daily S. boulardii, strain of S. cerevisiae 1 g or 4 × 109 cfu per day L. rhamnosus GG 1010-1011 cfu, twice daily S. boulardii, strain of S. cerevisiae 2–3 × 109 cfu for 28 days, followed for another 4 weeks L. rhamnosus HN001 + L. acidophilus NCFM 109 cfu each, once daily L. acidophilus + B. bifidum (Cultech strains) 2 × 1010 cfu each strain, once daily Prevention of C. difficile diarrhea in adults Safety of Probiotics. Are they safe in CLD, CKD, Immunosuppressed AC Pre-, Pro-, and Synbiotics: Do They Have a Role in Reducing Uremic Toxins? A Systematic Review and Meta-Analysis Rossi, Int J Nephrol. 2012 •19 studies analysed •Supportive evidence for the effectiveness of pre- and probiotics on reducing toxins •No notable adverse effects Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial Lumia, Clin Gastroenterol Hepatol. 2014 •160 subjects •New Delhi •Found to be effective in preventing HE in patients with cirrhosis •No adverse effects noted The efficacy and safety of probiotics in people with cancer: a systematic review Redman, Ann Oncol 2014 • 17 studies analyzed • 1530 patients • 5 case reports showed probiotic-related bacteraemia/fungaemia/positive blood cultures Extra GI uses of probiotics BS And many more……. • • • • • • • Recurrent UTI Vaginal infection Atopic diseases Food allergy Recurrent URTI Dental Caries VAP • Prevention of cancer • Immune Enhancement • Cardiovascular Risk Reduction • Obesity • Type 2 Diabetes mellitus Fecal Transplantation JJ • Fecal microbiota transplantation (FMT) is the process of transplantation of fecal bacteria from a healthy individual into a recipient. • Involves restoration of colonic flora by introducing healthy bacterial flora through infusion of stool from a healthy human donor. • First description of FMT published in 1958 by Eiseman and colleagues, surgeons from Colorado, who treated four critically ill patients with fulminant pseudomembranous colitis. • Hypothesis behind FMT rests on concept of bacterial interference. • Production of antimicrobial agents (Bacteriocins) by the introduced colonic flora. • Highly effective in treating recurrent C. difficile, and more effective than vancomycin alone. • Also used to treat other conditions including ulcerative colitis, constipation, irritable bowel syndrome and neurological conditions like multiple sclerosis and Parkinson’s disease. • Single to multiple infusions. • Donors tested for a wide array of bacterial and parasitic infections. • Infusions administered via various routes depending on suitability and ease - enema, colonoscope. • Modified form of fecal bacteriotherapy (Autologous Restoration of Gastrointestinal Flora - ARGF) • Autologous fecal sample provided by the patient before medical treatment is stored. Should the patient develop C. difficile, the sample is extracted with saline and filtered. The filtrate is freeze dried and enclosed in enteric coated capsules. Concluding remarks Thank you